• +1-646-491-9876
    • +91-20-67278686

    Search

    Premature Labor (Tocolysis) - Pipeline Review, H1 2015

    Premature Labor (Tocolysis) - Pipeline Review, H1 2015

    • Report Code ID: RW0001172189
    • Category Pharmaceuticals
    • No. of Pages 46
    • Publication Month Jan-15
    • Publisher Name Global Markets Direct
    Premature Labor (Tocolysis)-Pipeline Review, H1 2015

    Summary

    Publisher's, 'Premature Labor (Tocolysis)-Pipeline Review, H1 2015', provides an overview of the Premature Labor (Tocolysis)'s therapeutic pipeline.

    This report provides comprehensive information on the therapeutic development for Premature Labor (Tocolysis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Labor (Tocolysis) and special features on late-stage and discontinued projects.

    Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

    The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

    Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

    Scope

    - The report provides a snapshot of the global therapeutic landscape of Premature Labor (Tocolysis)
    - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in the therapeutics development for Premature Labor (Tocolysis) and enlists all their major and minor projects
    - The report summarizes all the dormant and discontinued pipeline projects
    - A review of the Premature Labor (Tocolysis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - A detailed assessment of monotherapy and combination therapy pipeline projects
    - Coverage of the Premature Labor (Tocolysis) pipeline on the basis of target, MoA, route of administration and molecule type
    - Latest news and deals relating related to pipeline products

    Reasons to buy

    - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Identify and understand important and diverse types of therapeutics under development for Premature Labor (Tocolysis)
    - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
    - Devise corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) pipeline depth and focus of Indication therapeutics
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
    Table of Contents
    Table of Contents 2
    List of Tables 4
    List of Figures 4
    Introduction 5
    Global Markets Direct Report Coverage 5
    Premature Labor (Tocolysis) Overview 6
    Therapeutics Development 7
    Pipeline Products for Premature Labor (Tocolysis)-Overview 7
    Pipeline Products for Premature Labor (Tocolysis)-Comparative Analysis 8
    Premature Labor (Tocolysis)-Therapeutics under Development by Companies 9
    Premature Labor (Tocolysis)-Therapeutics under Investigation by Universities/Institutes 10
    Premature Labor (Tocolysis)-Pipeline Products Glance 11
    Late Stage Products 11
    Clinical Stage Products 12
    Early Stage Products 13
    Unknown Stage Products 14
    Premature Labor (Tocolysis)-Products under Development by Companies 15
    Premature Labor (Tocolysis)-Products under Investigation by Universities/Institutes 16
    Premature Labor (Tocolysis)-Companies Involved in Therapeutics Development 17
    Actavis plc 17
    GlaxoSmithKline plc 18
    Kissei Pharmaceutical Co., Ltd. 19
    ObsEva SA 20
    Premature Labor (Tocolysis)-Therapeutics Assessment 21
    Assessment by Monotherapy Products 21
    Assessment by Target 22
    Assessment by Mechanism of Action 24
    Assessment by Route of Administration 26
    Assessment by Molecule Type 28
    Drug Profiles 30
    AT-814-Drug Profile 30
    Product Description 30
    Mechanism of Action 30
    R&D Progress 30
    bedoradrine sulfate-Drug Profile 31
    Product Description 31
    Mechanism of Action 31
    R&D Progress 31
    Drug for Postpartum Depression and Premature Labor-Drug Profile 33
    Product Description 33
    Mechanism of Action 33
    R&D Progress 33
    OBE-001-Drug Profile 34
    Product Description 34
    Mechanism of Action 34
    R&D Progress 34
    OBE-002-Drug Profile 35
    Product Description 35
    Mechanism of Action 35
    R&D Progress 35
    Progesterone Second Generation-Drug Profile 36
    Product Description 36
    Mechanism of Action 36
    R&D Progress 36
    retosiban-Drug Profile 37
    Product Description 37
    Mechanism of Action 37
    R&D Progress 37
    Small Molecule to Agonize Progesterone Receptor for Preterm Birth-Drug Profile 38
    Product Description 38
    Mechanism of Action 38
    R&D Progress 38
    Premature Labor (Tocolysis)-Recent Pipeline Updates 39
    Premature Labor (Tocolysis)-Dormant Projects 41
    Premature Labor (Tocolysis)-Discontinued Products 42
    Premature Labor (Tocolysis)-Product Development Milestones 43
    Featured News & Press Releases 43
    Aug 17, 2007: MediciNova Reports Phase Ib Clinical Study Results For MN-221 A Novel Treatment For Preterm Labor 43
    Mar 14, 2005: MediciNova Initiates A Phase I Clinical Trial With MN-221 43
    Mar 24, 2004: MediciNova Acquires Phase II Premature Labor Compound 44
    Appendix 45
    Methodology 45
    Coverage 45
    Secondary Research 45
    Primary Research 45
    Expert Panel Validation 45
    Contact Us 45
    Disclaimer 46

    List of Tables
    Number of Products under Development for Premature Labor (Tocolysis), H1 2015 7
    Number of Products under Development for Premature Labor (Tocolysis)-Comparative Analysis, H1 2015 8
    Number of Products under Development by Companies, H1 2015 9
    Number of Products under Investigation by Universities/Institutes, H1 2015 10
    Comparative Analysis by Late Stage Development, H1 2015 11
    Comparative Analysis by Clinical Stage Development, H1 2015 12
    Comparative Analysis by Early Stage Development, H1 2015 13
    Comparative Analysis by Unknown Stage Development, H1 2015 14
    Products under Development by Companies, H1 2015 15
    Products under Investigation by Universities/Institutes, H1 2015 16
    Premature Labor (Tocolysis)-Pipeline by Actavis plc, H1 2015 17
    Premature Labor (Tocolysis)-Pipeline by GlaxoSmithKline plc, H1 2015 18
    Premature Labor (Tocolysis)-Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 19
    Premature Labor (Tocolysis)-Pipeline by ObsEva SA, H1 2015 20
    Assessment by Monotherapy Products, H1 2015 21
    Number of Products by Stage and Target, H1 2015 23
    Number of Products by Stage and Mechanism of Action, H1 2015 25
    Number of Products by Stage and Route of Administration, H1 2015 27
    Number of Products by Stage and Molecule Type, H1 2015 29
    Premature Labor (Tocolysis) Therapeutics-Recent Pipeline Updates, H1 2015 39
    Premature Labor (Tocolysis)-Dormant Projects, H1 2015 41
    Premature Labor (Tocolysis)-Discontinued Products, H1 2015 42

    List of Figures
    Number of Products under Development for Premature Labor (Tocolysis), H1 2015 7
    Number of Products under Development for Premature Labor (Tocolysis)-Comparative Analysis, H1 2015 8
    Number of Products under Development by Companies, H1 2015 9
    Comparative Analysis by Clinical Stage Development, H1 2015 12
    Comparative Analysis by Early Stage Products, H1 2015 13
    Assessment by Monotherapy Products, H1 2015 21
    Number of Products by Top 10 Targets, H1 2015 22
    Number of Products by Stage and Top 10 Targets, H1 2015 23
    Number of Products by Top 10 Mechanism of Actions, H1 2015 24
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 24
    Number of Products by Top 10 Routes of Administration, H1 2015 26
    Number of Products by Stage and Top 10 Routes of Administration, H1 2015 27
    Number of Products by Top 10 Molecule Types, H1 2015 28
    Number of Products by Stage and Top 10 Molecule Types, H1 2015 29
    Actavis plc
    GlaxoSmithKline plc
    Kissei Pharmaceutical Co., Ltd.
    ObsEva SA

    Request for Sample

    Report Url http://www.reportsweb.com//premature-labor-tocolysis-pipeline-review-h1-2015&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//premature-labor-tocolysis-pipeline-review-h1-2015&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//premature-labor-tocolysis-pipeline-review-h1-2015&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments